Immunotherapy with antibody-targeted HLA class I complexes: results of in vivo tumour cell killing and therapeutic vaccination.
BACKGROUND: The delivery of antibody-targeted major histocompatibility complex (MHC) class I complexes containing immunogenic peptides to the surface of tumour cells allows cytotoxic T lymphocytes (CTLs) of non-tumour specificity to recognise and kill the tumour cell. Previous studies have demonstra...
Autori principali: | , , , , , , , , , , , |
---|---|
Natura: | Journal article |
Lingua: | English |
Pubblicazione: |
2007
|